Vir Biotechnology
157 hedge funds and large institutions have $3.87B invested in Vir Biotechnology in 2021 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 38 increasing their positions, 66 reducing their positions, and 24 closing their positions.
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
10% more funds holding
Funds holding: 143 → 157 (+14)
2.77% less ownership
Funds ownership: 61.95% → 59.19% (-2.8%)
18% less call options, than puts
Call options by funds: $34.5M | Put options by funds: $42.2M
33% less capital inflows, than outflows
Capital inflows: $208M | Capital outflows: $309M
42% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 66
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$28.1M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$24.3M |
| 3 |
Goldman Sachs
New York
|
+$24.1M |
| 4 |
MM
MWG Management
Road Town, Tortola,
British Virgin Islands
|
+$17.5M |
| 5 |
Morgan Stanley
New York
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$62.9M |
| 2 |
Iconiq Capital
San Francisco,
California
|
-$59.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$57M |
| 4 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
-$53.9M |
| 5 |
BlackRock
New York
|
-$8.79M |
VIR Hedge Fund Activity: Q1 2021 in Review
157 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2021, worth a combined $3.87B — up 83% from $2.11B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new VIR positions and 24 closed out — a net gain of 14 holders — while 38 added to existing stakes and 66 trimmed.
The largest buyer was Capital International Investors, adding an estimated $28.1M. The largest seller was AllianceBernstein, cutting an estimated $62.9M.
- 157 institutional investors held Vir Biotechnology (VIR) as of Q1 2021, up from 143 in Q4 2020.
- Funds reported $3.87B of Vir Biotechnology stock for Q1 2021, up 83% quarter-over-quarter.
- 38 funds opened new Vir Biotechnology positions in Q1 2021 and 24 closed out, a net change of +14 holders.
- The largest Vir Biotechnology buyer in Q1 2021 was Capital International Investors, an estimated $28.1M added.
- The largest Vir Biotechnology seller in Q1 2021 was AllianceBernstein, an estimated $62.9M sold.
Based on aggregated 13F filings for Q1 2021.